These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14689197)

  • 1. [Therapy of primary systemic vasculitis].
    de Groot K; Gross WL; Hellmich B
    Internist (Berl); 2003 Dec; 44(12):1541-8. PubMed ID: 14689197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides.
    de Groot K; Jayne D
    Clin Nephrol; 2005 Dec; 64(6):480-4. PubMed ID: 16370164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C;
    N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and management of small vessel vasculitides].
    Pettersson T; Karjalainen A
    Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of ANCA-associated systemic vasculitis.
    Belmont HM
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):60-6. PubMed ID: 17121492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ANCA-associated vasculitis].
    Holle JU
    Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?
    Flossmann O; de Groot K
    Nat Clin Pract Nephrol; 2007 May; 3(5):236-7. PubMed ID: 17457358
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic vasculitis: still a challenging disease.
    Buhaescu I; Covic A; Levy J
    Am J Kidney Dis; 2005 Aug; 46(2):173-85. PubMed ID: 16112036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Microscopic polyangiitis].
    Pagnoux C; Guilpain P; Guillevin L
    Presse Med; 2007 May; 36(5 Pt 2):895-901. PubMed ID: 17350793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
    N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
    Tervaert JW; Stegeman CA
    Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasculitis: clinical approach, pathophysiology and treatment.
    Kallenberg CG
    Wien Klin Wochenschr; 2000 Aug; 112(15-16):656-9. PubMed ID: 11020951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the use of biologics in vasculitides.
    Vishwanath S; Relan M; Shen L; Ambrus JL
    Curr Pharm Biotechnol; 2014; 15(6):558-62. PubMed ID: 25213365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of methotrexate in ANCA-associated vasculitides.
    Reinhold-Keller E; de Groot K
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S178-82. PubMed ID: 21044456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimisation of cyclophosphamide therapy in systemic vasculitis.
    Richmond R; McMillan TW; Luqmani RA
    Clin Pharmacokinet; 1998 Jan; 34(1):79-90. PubMed ID: 9474474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
    Jayne DR; Rasmussen N
    Mayo Clin Proc; 1997 Aug; 72(8):737-47. PubMed ID: 9276602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.